Julie Naud

486 citations

14 papers · 386 indexed · h-index 12

Co-authors: Christiane Yoakim William W. Ogilvie Bruno Haché Robert Déziel Jeff A. O’Meara Nathalie Goudreau Michael G. Cordingley Dale R. Cameron
Topics: HIV/AIDS drug development and treatment (6 papers)Hepatitis C virus research (5 papers)Pneumocystis jirovecii pneumonia detection and treatment (4 papers)
Cited by: Hepatology Organic Chemistry Virology
Journals: Journal of Medicinal Chemistry Bioorganic & Medicinal Chemistry Bioorganic & Medicinal Chemistry Letters
Partner nations: Canada Egypt Germany

In The Last Decade

Julie Naud

13 papers receiving 375 citations

Peers

Countries citing papers authored by Julie Naud

Since Specialization

Citations

This map shows the geographic impact of Julie Naud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie Naud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie Naud more than expected).

Fields of papers citing papers by Julie Naud

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie Naud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie Naud. The network helps show where Julie Naud may publish in the future.

Co-authorship network of co-authors of Julie Naud

This figure shows the co-authorship network connecting the top 25 collaborators of Julie Naud. A scholar is included among the top collaborators of Julie Naud based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie Naud. Julie Naud is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Synthesis and optimization of a novel series of HCV NS3 protease inhibitors: 4-Arylproline analogs 2013 ·Bioorganic & Medicinal Chemistry Letters ·François Bilodeau,Murray D. Bailey,(unknown),Josée Bordeleau,Pat Forgione,Michel Garneau,Élise Ghiro,Vida Gorys,Ted Halmos,(unknown),Mélissa Leblanc,Christopher T. Lemke,Julie Naud,Jeff A. O’Meara,Peter W. White,Montse Llinàs‐Brunet	4
2	Structure-based design of novel HCV NS5B thumb pocket 2 allosteric inhibitors with submicromolar gt1 replicon potency: Discovery of a quinazolinone chemotype 2013 ·Bioorganic & Medicinal Chemistry Letters ·Pierre L. Beaulieu,René Coulombe,Jianmin Duan,Gulrez Fazal,Cédrickx Godbout,Oliver Hucke,Araz Jakalian,(unknown),Olivier Lepage,Montse Llinàs‐Brunet,Julie Naud,Martin Poirier,Nathalie Rioux,Bounkham Thavonekham,George Kukolj,Timothy A. Stammers	21
3	Discovery of a Potent and Selective Noncovalent Linear Inhibitor of the Hepatitis C Virus NS3 Protease (BI 201335) 2010 ·Journal of Medicinal Chemistry ·Montse Llinàs‐Brunet,Murray D. Bailey,Nathalie Goudreau,(unknown),Josée Bordeleau,Michael Bös,Yves Bousquet,Michael G. Cordingley,(unknown),Pat Forgione,Michel Garneau,Élise Ghiro,Vida Gorys,Sylvie Goulet,Ted Halmos,Stephen H. Kawai,Julie Naud,Marc‐André Poupart,Peter W. White	57
4	Medicinal understory herbaceous species cultivated under different light and soil conditions in maple forests in southern Québec, Canada 2009 ·Agroforestry Systems ·Julie Naud,Alain Olivier,André Bélanger,Line Lapointe	16
5	The Use of Chemical Double‐Mutant Cycles in Biomolecular Recognition Studies: Application to HCV NS3 Protease Inhibitors 2008 ·ChemMedChem ·Stephen H. Kawai,Murray D. Bailey,Ted Halmos,Pat Forgione,Steven R. LaPlante,Montse Llinàs‐Brunet,Julie Naud,(unknown)	13
6	Potent triazolyl-proline-based inhibitors of HCV NS3 protease 2008 ·Bioorganic & Medicinal Chemistry Letters ·Julie Naud,Christopher T. Lemke,Nathalie Goudreau,(unknown),(unknown),Montse Llinàs‐Brunet,Pat Forgione	24
7	Optimization and determination of the absolute configuration of a series of potent inhibitors of human papillomavirus type-11 E1–E2 protein–protein interaction: A combined medicinal chemistry, NMR and computational chemistry approach 2007 ·Bioorganic & Medicinal Chemistry ·Nathalie Goudreau,Dale R. Cameron,Robert Déziel,Bruno Haché,Araz Jakalian,Éric Malenfant,Julie Naud,William W. Ogilvie,Jeff A. O’Meara,Peter W. White,Christiane Yoakim	24
8	Novel 8-Substituted Dipyridodiazepinone Inhibitors with a Broad-Spectrum of Activity against HIV-1 Strains Resistant to Non-nucleoside Reverse Transcriptase Inhibitors 2005 ·Journal of Medicinal Chemistry ·Jeff A. O’Meara,Christiane Yoakim,Pierre Bonneau,Michael Bös,Michael G. Cordingley,Robert Déziel,Louise Doyon,Jianmin Duan,Michel Garneau,Ingrid Guse,Serge Landry,Éric Malenfant,Julie Naud,William W. Ogilvie,Bounkham Thavonekham,Bruno Simoneau	15
9	Novel nevirapine-like inhibitors with improved activity against NNRTI-resistant HIV: 8-heteroarylthiomethyldipyridodiazepinone derivatives 2003 ·Bioorganic & Medicinal Chemistry Letters ·Christiane Yoakim,Pierre Bonneau,Robert Déziel,Louise Doyon,Jianmin Duan,Ingrid Guse,Serge Landry,Éric Malenfant,Julie Naud,William W. Ogilvie,(unknown),Raymond Plante,Bruno Simoneau,Bounkham Thavonekham,Michael Bös,Michael G. Cordingley	22
10	Discovery of the First Series of Inhibitors of Human Papillomavirus Type 11: Inhibition of the Assembly of the E1—E2—Origin DNA Complex 2003 ·ChemInform ·Christiane Yoakim,William W. Ogilvie,Nathalie Goudreau,Julie Naud,Bruno Haché,Jeff A. O’Meara,Michael G. Cordingley,Jacques Archambault,Peter W. White	1
11	Discovery of the first series of inhibitors of human papillomavirus type 11: inhibition of the assembly of the E1–E2–Origin DNA complex 2003 ·Bioorganic & Medicinal Chemistry Letters ·Christiane Yoakim,William W. Ogilvie,Nathalie Goudreau,Julie Naud,Bruno Haché,Jeff A. O’Meara,Michael G. Cordingley,Jacques Archambault,Peter W. White	53
12	Synthesis and antiviral activity of monobactams inhibiting the human cytomegalovirus protease 1999 ·Bioorganic & Medicinal Chemistry ·William W. Ogilvie,Christiane Yoakim,Florence Dô,Bruno Haché,Lisette Lagacé,Julie Naud,(unknown),Robert Déziel	41
13	Potent β-Lactam Inhibitors of Human Cytomegalovirus Protease 1998 ·Antiviral chemistry & chemotherapy ·Christiane Yoakim,(unknown),Dale R. Cameron,Catherine Chabot,Chantal Grand‐Maître,Ingrid Guse,Bruno Haché,Stephen H. Kawai,Julie Naud,(unknown),Raymond Plante,Robert Déziel	27
14	β-Lactam Derivatives as Inhibitors of Human Cytomegalovirus Protease 1998 ·Journal of Medicinal Chemistry ·Christiane Yoakim,William W. Ogilvie,Dale R. Cameron,Catherine Chabot,Ingrid Guse,Bruno Haché,Julie Naud,Jeff A. O’Meara,Raymond Plante,Robert Déziel	68

About Julie Naud

Julie Naud is a scholar working on Hepatology, Virology and Infectious Diseases, having authored 14 papers that have together received 386 indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (6 papers), Hepatitis C virus research (5 papers) and Pneumocystis jirovecii pneumonia detection and treatment (4 papers). The work is most often cited by research in Hepatology (72 citations), Organic Chemistry (200 citations) and Virology (29 citations). Julie Naud has collaborated with scholars based in Canada, Egypt and Germany. Frequent co-authors include Christiane Yoakim, William W. Ogilvie, Bruno Haché, Robert Déziel, Jeff A. O’Meara, Nathalie Goudreau, Michael G. Cordingley, Dale R. Cameron, Ingrid Guse and Peter W. White. Their work appears in journals such as Journal of Medicinal Chemistry, Bioorganic & Medicinal Chemistry and Bioorganic & Medicinal Chemistry Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact